Athenex Inc (ATNX) Scheduled to Post Quarterly Earnings on Monday

Athenex Inc (NASDAQ:ATNX) will be announcing its earnings results before the market opens on Monday, August 14th.

Athenex Inc (NASDAQ:ATNX) opened at 14.61 on Friday. The firm has a 50-day moving average of $16.83 and a 200 day moving average of $16.37. Athenex Inc has a 12 month low of $11.21 and a 12 month high of $20.79. The firm’s market capitalization is $594.42 million.

WARNING: “[[title]]” was first posted by [[site]] and is the sole property of of [[site]]. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at [[permalink]].

Separately, Deutsche Bank AG assumed coverage on shares of Athenex in a research report on Monday, July 10th. They set a “buy” rating and a $20.00 price objective on the stock.

In other news, CEO Johnson Yiu Nam Lau purchased 25,200 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The shares were bought at an average price of $11.00 per share, for a total transaction of $277,200.00. Following the purchase, the chief executive officer now directly owns 2,722,722 shares in the company, valued at approximately $29,949,942. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Song-Yi Zhang purchased 328,637 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The stock was purchased at an average price of $11.00 per share, for a total transaction of $3,615,007.00. Following the purchase, the director now owns 4,000 shares in the company, valued at $44,000. The disclosure for this purchase can be found here.

An institutional investor recently bought a new position in Athenex stock. Vanguard Group Inc. purchased a new position in Athenex Inc (NASDAQ:ATNX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,000 shares of the company’s stock, valued at approximately $800,000. Vanguard Group Inc. owned 0.12% of Athenex at the end of the most recent quarter. 0.12% of the stock is currently owned by hedge funds and other institutional investors.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.